The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging.

Javad Azadi, My-Linh Nguyen, Antione Leroy, Katarzyna J Macura, Michael A Gorin, Steven P Rowe

Open access · greenAbstract readReview

In one paragraph

Review in The British journal of radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 43% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Javad Azadi1 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine , Baltimore, MD , USA.

My-Linh Nguyen1 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine , Baltimore, MD , USA.

Antione Leroy2 Koelis Inc. , Cambridge , MA, USA.

Katarzyna J Macura1 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine , Baltimore, MD , USA.

Michael A Gorin1 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine , Baltimore, MD , USA.

Steven P Rowe1 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine , Baltimore, MD , USA.

Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasingly robust body of evidence indicates that multiparametric MRI (mpMRI) prior to prostate biopsy can improve the detection of clinically significant prostate cancer while avoiding unnecessary biopsies. As a result, the use of mpMRI and biopsy platforms that allow for the real-time fusion of mpMRI and transrectal ultrasound images is now routinely used in clinical practice. On the horizon, molecular imaging offers the promise of improved sensitivity relative to mpMRI and early data would suggest that the combination of mpMRI and positron emission tomography using radiotracers targeting prostate-specific membrane antigen provide a more accurate assessment than either modality alone. In this review, we examine the current role of imaging to aid in the initial diagnosis of prostate cancer.

Indexed as

Molecular ImagingHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleProstateProstate-Specific AntigenProstatic NeoplasmsUltrasonographyUnnecessary ProceduresProstate-Specific Antigen

Identifiers

PMID30048145

DOI10.1259/bjr.20170960

PMCPMC6350472

OpenAlexW2883933200

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.